Vignesh Packiam, MD
@VigneshPackiam
Associate Prof @RutgersCancer @rwjurology | Previously at @UIowa_Urology | Alum @MayoClinic @Uro_Onc, @UChicagoUro, @PittMedAlum, @UWBadgers| Views my own
💯
"Good decision-making does not entail hiding a professional opinion; it requires engaging in genuine deliberation with a patient." Read this Viewpoint about the complexities of surgical decision-making. ja.ma/44Tlrug
📢 The EA8212 “BRIDGE” study will officially close to accrual on July 24. If you have patients interested they will need to be randomized by then 👏 Huge thanks to all investigators—& especially patients—for helping enroll nearly 900 participants in just 2.5 years. @eaonc
My friend is famous
Nice work by @ryansteinbergmd helping @USATODAY explain the causes of kidney stones and how they're treated.
👏 Big congrats to @uroegg! New chair of urology at @UclaUrology
Completely agree with this. Have clarified a lot of questions and answers in the paper writing process
✍️ Writing is thinking. 👉🏼A powerful editorial in Nature Reviews Bioengineering (Vol. 3, p. 431, 2025) reminds us of something timeless: in science, writing is far more than reporting results. It’s a way of sharpening thought. 👉🏼Even in an age shaped by large-language models,…
Had a blast chatting with @VigneshPackiam - one of the most knowledgeable people I know in the field of bladder cancer.
📺 In our latest video series, Drs. @VigneshPackiam and @NitinYerram explore the latest advances in #NMIBC, including combination #immunotherapy with BCG: buff.ly/D11fEFh 👉 In part 1 of the series, they provide a foundational overview of NMIBC, highlighting how BCG has…
📺 In our latest video series, Drs. @VigneshPackiam and @NitinYerram explore the latest advances in #NMIBC, including combination #immunotherapy with BCG: buff.ly/D11fEFh 👉 In part 1 of the series, they provide a foundational overview of NMIBC, highlighting how BCG has…
Thanks for the shoutout @LauraBukavinaMD ! Alot for a tweet, but want to add a few caveats: - This cohort enriched for prostatic urethral UC (19% prior to Val/Doce, and 27% had history of). Very high risk. And almost universally excluded from trials - an unmet need. In that…
New study on Valrubicin + Docetaxel as salvage for BCG unresponsive/exposed NMIBC @EurUrolFocus @VigneshPackiam 🚨 1 in 3 patients progression within 5 years. ⚠️ prostatic involvement = 2x risk of progression (p=0.02) 💢 53% adverse event rate 👎 41% recurrence-free at 3 yrs…
Long-term follow-up report on salvage sequential intravesical Valrubicin and Docetaxel (Val/Doce) - High-Risk cohort (44% BCG-unresponsive, 96% Gem/Doce unresponsive, 20% prostatic urethral involvement) - 1y RFS 58% - 5y PFS 70% - 1% G3+ AEs Needs prospective eval! @eaonc
What a fantastic tool! Thanks for sharing. @KariTikkinen @GU_BigWhacks @saumyg @VigneshPackiam @UroAlsyouf @douglawi @LeileiXiaUro @alirezaghoreifi @domesypantsx3
🩸💥 Many have asked: “Where did the EAU #thromboprophylaxis guideline go?” Don’t worry. Check out cluevte.org 🚀 ✅ Not just #urology, also #gynecology & abd #surgery ✅ Procedure-specific VTE & bleeding risks ✅ Free interactive tool + static infographics #EBM
The July 2025 Eur Urol Podcast has dropped! Your Hosts @declangmurphy @NikitaB0709 chat about VHL with Dr Marston Linehan, and novel intravesical therapies with Dr Saum Ghodoussipour. Plus Dr Eoin Dinneen picks out a few other highlights in our July ed youtube.com/watch?v=Vodwjg…
Biomarkers for gemcitabine docetaxel in non-muscle invasive #BladderCancer. @VigneshPackiam @RutgersCancer joins @JoepJdeJong @ErasmusMC to discuss promising results for non-muscle invasive bladder cancer, with potential biomarkers on the horizon for precision medicine. #WatchNow…
Vignesh T. Packiam, MD, (@VigneshPackiam) outlines the mechanism of action and dosing for detalimogene voraplamid in NMIBC. @rwjurology urologytimes.com/view/vignesh-p…
Thanks to all my colleagues (@ChadTracyMD @baerickson29 @HougenHY @AnnahVollstedt @VigneshPackiam #MikeODonnell), collaborators (@rkorets @RdonalisioMD), friends & family on this crazy journey (and for listening to all my inane research ideas). Couldn’t have done it without u!
🎉 Congratulations to @ryansteinbergmd on his promotion to Clinical Associate Professor! Since joining our faculty in 2020, his dedication to patient care, training, and research has been exemplary. 👏
🚨 NEW in #EuropeanUrology By @saumyg @UrogerliMD @spsutkaMD @tbivala1 @joanfundi et al Can novel intravesical therapies change the game for non–muscle-invasive bladder cancer? This systematic review explores: ✅ BCG-based combos ✅ Gene & immune therapies ✅ Innovative drug…
Awe-inspiring 1st week for our patients & our 💪🏼talented multi-disciplinary GU team at the Jack & Sheryl Morris Cancer Center @RutgersCancer @rwjurology #UroSoMe @SUO_YUO @UroOnc @NYSAUA #NewJersey's only @theNCI designated comprehensive #cancer center
jamanetwork.com/journals/jaman… TMT for MIBC is a crucial treatment option for our patients. 💵However, its current costs are unsustainable, especially with the growing interest in expanding its use.
***Only 1 week remaining*** Deadline is June 30th to submit abstracts and travel award applications for IBCN 2025 - Munich, Germany! ibcnweb.com/ibcn-abstract-… ibcnweb.com/travel_award/ @pcvblack @LDyrskjot @ttodenhoefer @Roland3097 @mouwlab @CanImmun @jdamrauer
Thrilled to be working together @VigneshPackiam
Excited to share this paper which has been many years in the making! This is the first publication of a predictive (AI-histology based) biomarker to guide rational use of BCG vs Gem/Doce for newly diagnosed HG NMIBC pubmed.ncbi.nlm.nih.gov/40287344/ Curves say it all 👇🏾
Excited to share our @valarlabs publication in @EUplatinum validating Vesta Risk Stratify computational histology AI biomarkers to predict recurrence and progression in High Grade Ta Bladder Cancer. (1/5) Publication: authors.elsevier.com/c/1lFoD14kpm0h…